GB9827279D0 - Treatment of coronary and peripheral ischemia using an antithrombotic agent and an angiogenesis promoter - Google Patents

Treatment of coronary and peripheral ischemia using an antithrombotic agent and an angiogenesis promoter

Info

Publication number
GB9827279D0
GB9827279D0 GBGB9827279.2A GB9827279A GB9827279D0 GB 9827279 D0 GB9827279 D0 GB 9827279D0 GB 9827279 A GB9827279 A GB 9827279A GB 9827279 D0 GB9827279 D0 GB 9827279D0
Authority
GB
United Kingdom
Prior art keywords
coronary
angiogenesis
antithrombotic agent
angiogenesis promoter
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB9827279.2A
Other versions
GB2332373A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9806705.1A external-priority patent/GB9806705D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of GB9827279D0 publication Critical patent/GB9827279D0/en
Publication of GB2332373A publication Critical patent/GB2332373A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method for treating a patient having coronary and/or peripheral ischemic syndrome by administering to the patient an effective amount of an antithrombotic agent, e.g. a glycoprotein IIb/IIIa antagonist, a thrombin inhibitor, a factor Xa inhibitor, or a low molecular weight heparin, and an effective amount of an angiogenesis promoter, e.g. a vascular endothelial growth factor or a fibroblast growth factor. Administration of the angiogenesis promoters may be by any suitable means known to persons skilled in the art, e.g. via bolus injection, continuous intravenous administration, coated stent implantation and gene transfer, which provides localized or systemic delivery of the angiogenesis promoter at the ischemic tissue.
GB9827279A 1997-12-19 1998-12-11 Treatment of coronary and/or peripheral ischemia using an antithrombotic agent and an angiogenesis promoter Withdrawn GB2332373A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6825797P 1997-12-19 1997-12-19
GBGB9806705.1A GB9806705D0 (en) 1998-03-27 1998-03-27 Treatment of coronary and peripheral ischemia using an antihrombotic agent and an angiogenesis promoter

Publications (2)

Publication Number Publication Date
GB9827279D0 true GB9827279D0 (en) 1999-02-03
GB2332373A GB2332373A (en) 1999-06-23

Family

ID=26313388

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9827279A Withdrawn GB2332373A (en) 1997-12-19 1998-12-11 Treatment of coronary and/or peripheral ischemia using an antithrombotic agent and an angiogenesis promoter

Country Status (1)

Country Link
GB (1) GB2332373A (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4643501A (en) * 2000-02-04 2001-08-14 Flanders Interuniversity Institute For Biotechnology (Vib) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
US7727971B2 (en) 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
US6930089B2 (en) 2000-02-04 2005-08-16 D. Collen Research Foundation Vzw Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke
US7105168B1 (en) 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
AU5523701A (en) * 2000-04-06 2001-10-23 Wayne P Franco Methods of using growth factors for treating heart disease
GB0120690D0 (en) 2001-08-24 2001-10-17 Novartis Ag Organic compounds
AU2002363369B2 (en) * 2001-10-15 2008-08-21 Janssen Pharmaceutica N.V. Substituted 4-phenyl-4-(1H-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
GB0414441D0 (en) * 2004-06-28 2004-07-28 Imp College Innovations Ltd Improved anti-viral compositions
DE602006017071D1 (en) * 2005-01-25 2010-11-04 Five Prime Therapeutics Inc COMPOSITIONS AND METHODS OF TREATING HEART DISEASES
WO2009132457A1 (en) * 2008-05-02 2009-11-05 University Of Western Ontario Fgf-9 and its use relating to blood vessels
CN105879130A (en) * 2016-06-08 2016-08-24 刘厂辉 Novel drug-coated stent
EP3710043B1 (en) * 2017-11-16 2024-04-17 Universite d'Aix-Marseille Fgf10 for the treatment of heart diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035615A1 (en) * 1996-03-27 1997-10-02 Merck & Co., Inc. Compositions and methods for inhibiting clot formation

Also Published As

Publication number Publication date
GB2332373A (en) 1999-06-23

Similar Documents

Publication Publication Date Title
GB9827279D0 (en) Treatment of coronary and peripheral ischemia using an antithrombotic agent and an angiogenesis promoter
Robson The role of growth factors in the healing of chronic wounds
EP0565620B1 (en) Mitotoxin for treatment of vascular injury
Harker et al. Thrombin hypothesis of thrombus generation and vascular lesion formation
US6297219B1 (en) Site-specific instillation of cells or site-specific transformation of cells and kits therefor
US6660034B1 (en) Stent for increasing blood flow to ischemic tissues and a method of using the same
US8455453B2 (en) Use of VEGF-D gene to prevent restenosis
CA2212537A1 (en) Therapeutic inhibitor of vascular smooth muscle cells
Muller et al. Colchicine and antineoplastic therapy for the prevention of restenosis after percutaneous coronary interventions
WO2001013031A3 (en) Dose of an angiogenic factor and method of administering to improve myocardial blood flow
EP0852491A4 (en) Use of heparinases to decrease inflammatory responses
Tanguay et al. Prevention of in-stent restenosis via reduction of thrombo-inflammatory reactions with recombinant P-selectin glycoprotein ligand-1
ATE485825T1 (en) THERAPEUTIC INHIBITORS OF VASCULAR SMOOTH CELLS
JP7343305B2 (en) Compositions and methods for immunomodulation by anti-LYST
Dosne et al. Tumor necrosis factor (TNF) stimulates plasminogen activator inhibitor (PAI) production by endothelial cells and decreases blood fibrinolytic activity in the rat
Kleiman et al. Evolving revascularization approaches for myocardial ischemia
Bartorelli et al. Local heparin delivery prior to coronary stent implantation: acute and six‐month clinical and angiographic results
Atkinson Ancrod in the treatment of acute ischaemic stroke
WO2002058720A3 (en) Angiogenically effective unit dose of fgf-2 and method of use
ATE279937T1 (en) FGF-2 ANGIOGENIC EFFECTIVE UNIT DOSE AND ITS USE
Kagan et al. Mediators of restenosis
Häyry et al. Blockade of growth factor synthesis and growth factor action: two possible sites of interference in allograft vessel disease and coronary bypass or balloon injury
US20020034505A1 (en) Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
JPH09151137A (en) Medicine for inhibiting multiplication of smooth muscle cell
Nugent et al. Local drug delivery and tissue engineering regulate vascular injury

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)